Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
Edgewise Therapeutics’ hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the company’s shares soaring.
All Posts in "News Team"
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
William McEwan, Ph.D., spent years unraveling how an antiviral protein, tripartite motif-containing 21 (TRIM21), protects our cells from infection. Working in the lab of Leo James, Ph.D., McEwan and collaborators realized that TRIM21 marks viruses to be destroyed by the cell’s waste disposal system—but only activates when enough of the proteins cluster together.
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis (MASH) after three different doses of its drug candidate significantly slashed liver fat at 12 weeks. Despite the company’s enthusiasm, the results failed to impress investors.
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the knock-back, accusing the agency of sending a complete response letter that generally disregarded the evidence.
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic.
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to lay off staff.
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
Basilea Pharmaceutica’s work developing new antifungals has received a significant boost from the U.S. Department of Health and Human Services, which has signed off on up to $268 million of funding to the Swiss company over more than a decade.
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 million for its “plug-and-play” tech developed in the lab of—and with cells from—George Church, Ph.D.
How the Stock Market Defied Expectations Again This Year, by the Numbers
What a wonderful year 2024 has been for investors
US Applications for Unemployment Benefits Hold Steady, but Continuing Claims Rise to 3-Year High
The number of Americans applying for unemployment benefits held steady last week, though continuing claims rose to the highest level in three years
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Jasper dials up dose after complete responses come and go quickly in hives trial
Novartis channels Gargamel, terminating midphase SMURF1 trial
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen